- Original research
- Open Access
The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
© The Author(s). 2017
- Received: 27 April 2017
- Accepted: 21 July 2017
- Published: 2 August 2017
The anticoagulated trauma patient presents a particular challenge to the critical care physician. Our understanding of these patients is defined and extrapolated by experience with patients on warfarin pre-injury. Today, many patients who would have been on warfarin are now prescribed the Direct Oral Anticoagulants (DOACs) a class of anticoagulants with entirely different mechanisms of action, effects on routine coagulation assays and approach to reversal.
Trauma registry data from Toronto’s (Ontario, Canada) two Level 1 trauma centres were used to identify patients on oral anticoagulation pre-injury from June 1, 2014 to June 1, 2015. The trauma registry and medical records were reviewed and used to extract demographic and clinical data.
We found 81 patients were on oral anticoagulants pre-injury representing 3.2% of the total trauma population and 33% of the orally anticoagulated patients were prescribed a DOAC prior to presentation. Comparison between the DOAC and warfarin groups showed similar age, mechanisms of injury, indications for anticoagulation, injury severity score and rate of intracranial hemorrhage. Patients on DOACs had higher initial mean hemoglobin vs warfarin (131 vs 120) and lower serum creatinine (94.8 vs 129.5). The percentage of patients receiving a blood transfusion in the trauma bay and total in-hospital transfusion was similar between the two groups however patients on DOACs were more likely to receive tranexamic acid vs patients on warfarin (32.1% vs 9.1%) and less likely to receive prothrombin concentrates (18.5% vs 60%). Patients on DOACs were found to have higher survival to discharge (92%) vs patients on warfarin (72%).
Patients on DOACs pre-injury now represent a significant proportion of the anticoagulated trauma population. Although they share demographic and clinical similarities with patients on warfarin, patients on DOACs may have improved outcomes despite lack of established drug reversal protocols and challenging interpretation of coagulation assays.
Level of Evidence: III; Study Type: Retrospective Review.
- Direct oral anticoagulants
Trauma patients who are on oral anticoagulation pre-injury are a vulnerable subset of the trauma population and account for approximately 4% of patients presenting with traumatic injury . These patients tend to be older and have multiple medical comorbidities. Furthermore, pre-injury anticoagulation has been shown to be an independent predictor of mortality [2, 3].
Current literature and management strategies are based on experience with patients on Vitamin K antagonists (e.g. warfarin). In the last several years the direct oral anticoagulants (DOACs) including dabigratan etexilate (dabigatran) a direct thrombin inhibitor as well as rivaroxaban, apixaban and edoxaban which are direct factor Xa inhibitors have reached the market. Large randomized control trials studying these agents for stroke prophylaxis as well as prophylaxis and treatment of venous thromboembolic disease (VTEs) have established improved safety and similar efficacy compared to warfarin [4–10]. These results combined with standardized dosing and elimination of blood monitoring have led to the widespread use of DOACs in clinical practice.
Although promising, use of DOACs pose challenges to acute care providers from both an assessment and management perspective. Due to their mechanism of action, DOAC use is associated with non-dose dependent effects on standard coagulation assays, such as the activated partial thromboplastin time (aPTT) and prothrombin time (PT) or international normalized ratio (INR) . When initially approved, a major concern was the lack of a specific reversal agent for instances of life-threatening hemorrhage or emergency surgery. Idarucizumab, a dabigatran reversal agent has recently been approved for use and direct Xa inhibitor reversal agents are expected to be approved in the near future. However, their clinical effectiveness and rational use in the setting of trauma is not yet well characterized.
As increasing numbers of the general population are put on DOACs, an increasing number of trauma patients who would have previously been on warfarin pre-injury will be presenting to trauma services on DOACs. Here we present data from a retrospective cohort using two trauma registries to characterize the clinical characteristics of the anticoagulated trauma patient population presenting to our Toronto-based trauma centres.
Participants were identified using the trauma registries at St. Michael’s Hospital (SMH) and Sunnybrook Health Sciences Centre (SHSC) which are both Urban, Level 1 trauma centres in Toronto, Canada. The trauma registries at both sites collect standardized data in-line with the American College of Surgeons Trauma Quality Improvement Program (TQIP) guidelines which are widely used in over 450 sites across North America. Demographic data and clinical outcomes for all patients admitted to the trauma service at SMH and SHSC are systematically tracked and maintained in validated databases. Both registries are routinely reviewed by the Canadian Institute of Health Information (CIHI) and the National Trauma Databank in the United States. Both systems have data validators that are used to ensure accuracy of the Registry Database; in addition, internal monthly, quarterly and annual data quality and inter-rater reliability reviews are performed to ensure data accuracy and reliability. Patients were identified by searching for trauma patients presenting from June 1, 2014 to June 1, 2015 who were identified as having a “bleeding disorder” which included oral anticoagulation or if they had atrial fibrillation as a comorbidity. These charts were screened by a trained reviewer to verify pre-injury oral anticoagulant prescription and then demographic and clinical data was extracted from the trauma registry dataset and the electronic medical record. Descriptive statistics were performed with Microsoft Excel. This study was reviewed and approved by the Sunnybrook Health Sciences Centre Research Ethics Board (076–2015) and the St. Michael’s Hospital Research Ethics Board (15–027). No patient consent was needed to collect information from both institutions' trauma registries.
Demographic & clinical characteristics of orally anticoagulated trauma patients
Indication for anticoagulation
Prosthetic heart valves
Mechanism of Injury
Motor vehicle collision
Injury scores, outcomes & lab values for orally anticoagulated trauma patients
Survival to Discharge
Blood product & coagulation assays for orally anticoagulated trauma patients
Anti Xa inhibitors
Trauma bay pRBC transfusion %
Total pRBC transfusion
aPTT >35 s
Although DOACs have been widely adopted in clinical practice there is a paucity of studies examining the effects of DOAC use in the Canadian trauma population. In addition, to our knowledge, this study is the first to examine transfusion and coagulation assay data in orally anticoagulated trauma patients since adoption of the DOACs. We have characterized a shift in oral anticoagulant therapy in trauma patients; a third of patients studied were on DOAC therapy. We suspect that this trend will continue as use of DOACs continues to rise.
In our study the warfarin group and the DOAC group had similar rates of pRBC transfusion on both initial presentation and cumulatively while in hospital however there were differences in use of hemostatic agents namely PCC and TXA. Since approval, caution against the use of DOACs has related to the lack of a specific reversal agent to manage life-threatening hemorrhage or need for emergent surgeries . In lieu of a specific reversal agent, recommendations have been centered on supportive care, general hemostatic measures and judicious use of factor concentrates which have been shown to reduce anticoagulant activity in healthy individuals and ex-vivo studies . The clinical benefit of such interventions however, is not well studied and in our practice setting there is considerable ambivalence regarding their use. The RE-VERSE AD trial studied the effects of giving Idarucizumab, a monoclonal antibody against free and thrombin bound dabigatran, to patients with life-threatening hemorrhage including “trauma-related” or requiring urgent surgery taking dabigatran and found that idarucizumab caused rapid reversal of anticoagulation . The ANNEXA-A and ANNEXA-R trials studied the effects of giving andexanet alpha, an anti-factor Xa decoy protein, to healthy volunteers taking apixaban or rivaroxaban and was found to rapidly reverse anticoagulation . Idarucizumab was recently approved for clinical use by the US Food and Drug Administration and Health Canada. Andexanet alpha is currently being studied in patients with bleeding on Factor Xa Inhibitors. It remains to be seen how introduction of these agents will affect clinical practice and patient outcomes such as mortality and need for transfusion.
Our findings related to lower mortality with DOACs are similar to findings by Maung et al., who recently published a large retrospective study using trauma registry data also comparing patient on DOACs vs. warfarin . Other literature comparing mortality for bleeding patients taking DOACs have come from sub-group analysis of the RE-LY trial as well as series of patients suffering all-cause ICH. Sub-group analysis of the RE-LY trial found that mortality for combined spontaneous and traumatic ICH in patients was similar for patients taking dabigatran versus warfarin although the overall event rate was lower in the dabigatran group . Alonso et al.  reported a large series of all-cause ICH in patients taking either dabigatran or warfarin derived from healthcare databases and found no difference in mortality between the two groups. Our study and Maung et al. included both intra- and extracranial injuries and excluded spontaneous ICH. It is possible that selection bias due to the inclusion of patients with extracranial injury affected outcomes. Another factor which may have affected mortality is anticoagulant activity at time of injury, in our study a greater proportion of patients taking VKAs had abnormal coagulation assays versus the DOAC group although these assays have limited utility when assessing anticoagulant activity induced by DOACs.
Our study does have limitations that must be considered when evaluating our results. The trauma registries used are not specifically designed to survey oral anticoagulant use and it is possible that study participants have been missed, however our finding of 3.2% oral anticoagulant exposure in trauma patients is in-line with previous publications . Our dataset was not able to capture time since last medication ingestion and given the shorter half-life of the DOACs, some patients may have had sub-therapeutic serum drug levels at time of assessment and thus lower risk of bleeding. Advanced coagulation studies such as the dilute-thrombin time (Hemoclot assay) and drug specific anti-Xa assays are available at some of our institutions but are not part of routine “trauma blood work” and are available only in consultation with the hematology service. Regular use of these assays would have allowed for definitive evaluation of anticoagulant activity at time of injury. We have however, reported the proportion of patients with abnormal “routine” coagulation test results as a surrogate of anticoagulant activity, although we recognize their limited reliability in the detection of DOAC drug presence (i.e. a normal test result does not definitively rule out DOAC presence).
Our study found that trauma patients taking DOACs pre-injury shared many clinical similarities with patients taking VKAs including indication for anticoagulation, mechanism of injury, presence of ICH, ISS and GCS. We did find that mortality was lower in patients taking DOACs pre-injury, however the percentage of patients with abnormal coagulation assays was lower in the DOAC group. We believe ongoing surveillance by trauma registries and ongoing studies are needed in this area as our ageing population are increasingly prescribed DOACs. Future studies which incorporate advanced coagulation assays to definitively measure anticoagulant activity and assessment of benefit of new reversal agents would be particularly valuable.
The authors have no sources of funding to declare.
Availability of data and materials
The data from this study was completely anonymous and housed under a trauma registry and is available if requested by the journal. Please contact author for data requests.
BW was the primary author; responsible for literature search, study design, data collection, data analysis, data interpretation, manuscript writing. AA participated in literature search, study design, data collection, data analysis, data interpretation, manuscript writing and critical revisions. SR, MS and BN participated in study design and critical revisions. AM and AP participated in data collection and critical revisions. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was reviewed and approved by the Sunnybrook Health Sciences Centre Research Ethics Board (076–2015) and the St. Michael’s Hospital Research Ethics Board (15–027). No patient consent was needed to collect information from both institutions trauma registries.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the national trauma databank. Arch Surg. 2011;146:565–70.View ArticlePubMedGoogle Scholar
- Batchelor JS, Grayson A. A meta-analysis to determine the effect of preinjury antiplatelet agents on mortality in patients with blunt head trauma. Br J Neurosurg. 2012;27:12–8.View ArticlePubMedGoogle Scholar
- Bonville DJ, Ata A, Jahraus CB, Arnold-Lloyd T, Salem L, Rosati C, et al. Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. Surgery. 2011;150:861–8.View ArticlePubMedGoogle Scholar
- Investigators TE. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.View ArticleGoogle Scholar
- Investigators TE-P. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.View ArticleGoogle Scholar
- Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.View ArticlePubMedGoogle Scholar
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.View ArticlePubMedGoogle Scholar
- Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.View ArticlePubMedGoogle Scholar
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.View ArticlePubMedGoogle Scholar
- Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.View ArticlePubMedGoogle Scholar
- Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné J-M, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thrombosis J. 2014;12:24.View ArticleGoogle Scholar
- Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365:2039–40.View ArticlePubMedGoogle Scholar
- Siegal D. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39(3):395–402.Google Scholar
- Pollack CVJ, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.View ArticlePubMedGoogle Scholar
- Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.View ArticlePubMedGoogle Scholar
- Maung AA, Bhattacharya B, Schuster KM, Davis KA. Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin. J Trauma Acute Care Surg. 2016;81:652–7.View ArticlePubMedGoogle Scholar
- Hart RG, Diener H-C, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43:1511–7.View ArticlePubMedGoogle Scholar
- Alonso A, Bengtson LGS, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke. 2014;45:2286–91.View ArticlePubMedPubMed CentralGoogle Scholar